Agno Pharma
Agno Pharma, a prominent player in the pharmaceutical industry, is headquartered in Switzerland and operates extensively across Europe and Asia. Founded in 2005, the company has established itself as a leader in the development and manufacturing of high-quality generic and specialty pharmaceuticals. Agno Pharma's core offerings include a diverse range of injectable medications and complex generics, distinguished by their rigorous quality standards and innovative formulations. The company has achieved significant milestones, including numerous regulatory approvals that underscore its commitment to excellence. With a strong market position, Agno Pharma is recognised for its contributions to healthcare, particularly in oncology and pain management. Its dedication to research and development continues to drive growth and enhance patient outcomes, solidifying its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Agno Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agno Pharma's score of 30 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Agno Pharma's reported carbon emissions
In 2023, Agno Pharma reported carbon emissions of approximately 50.1 million tonnes CO2e, with 59,000 tonnes from Scope 2 and about 50.1 million tonnes from Scope 3 emissions. This represents a slight increase from 2022, where Scope 3 emissions were around 47.9 million tonnes CO2e. Notably, Scope 1 emissions were recorded at zero tonnes CO2e in 2023, a significant reduction from 7,000 tonnes in 2018. Agno Pharma has set ambitious climate commitments, aiming for a 65% reduction in Scope 1 and 2 greenhouse gas emissions by 2025, using 2018 as the baseline year. Additionally, the company targets a 25% reduction in Scope 3 emissions by 2030. Looking further ahead, Agno Pharma is committed to achieving net-zero value chain greenhouse gas emissions by no later than 2050, with a long-term science-based target currently in development. These initiatives reflect Agno Pharma's dedication to addressing climate change and reducing its overall carbon footprint across all scopes of emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2018 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 7,000 | - | - |
| Scope 2 | 107,000 | - | 00,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Agno Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
